Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 1
Abstract
Purpose: To compare morphometric changes in the chorioretinal complex after anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with pathologic myopia (PM)-related choroidal neovascularization (CNV) versus those with age-related macular degeneration (AMD)-related CNV. Materials and Methods: This was a prospective comparative uncontrolled cohort study involving 156 patients (169 eyes) with subfoveal CNV. Of these, 82 (85 eyes) had pathologic PM-related CNV, and 74 (85 eyes) had AMD-related CNV. Patients with AMD underwent a treatment regimen of three mandatory monthly 0.5-mg (0.05-mL) intravitreal ranibizumab injections followed by pro re nata (PRN) dosing according to re-treatment criteria. Patients with PM underwent a treatment regimen of two mandatory monthly 0.5-mg (0.05-mL) intravitreal ranibizumab injections or 2-mg (0.05-mL) intravitreal aflibercept injections followed by PRN dosing according to re-treatment criteria. Primary outcomes were central retinal thickness (CRT) and CNV thickness at month 12. Secondary outcomes included best-corrected visual acuity (BCVA) and number of injections at month 12. Results: At month 12, (1) mean OCT-based CRT in AMD and PM groups decreased from 349 μm to 258 μm (P = 0.00), and from 306 μm to 228 μm (P = 0.00), respectively, and (2) mean CNV thickness in AMD and PM groups decreased from 183 μm to 108 μm (P = 0.00), and from 229 μm to 173 μm (P = 0.00), respectively. In addition, mean (SD) BCVA in the AMD group improved from 0.25 (0.23) at baseline to 0.33 (0.29), whereas that in the PM group improved from 0.17 (0.11) to 0.35 (0.19). The mean number of anti-VEGF injections was 5.4 (2.1) and 2.2 (0.6) for the AMD and PM groups, respectively, with the between-group difference being statistically significant (P = 0.00). Conclusions: Decrease in central retinal thickness and improvements in visual acuity after anti-VEGF treatment for AMD-related subfoveal CNV were similar to those after anti-VEGF treatment for PM-related subfoveal CNV. At month 12, percent decreases in CNV thickness compared to baseline were 26% and 41% for anti-VEGF treated patients with AMD-related and PM-related subfoveal CNV, respectively. Patients with AMD-related CNV required, on average, 3 more anti-VEGF injections than those with PM-related CNV.
Authors and Affiliations
O. Blavatska, T. Kustryn, A. Korol
Keywords
Related Articles
- EP ID EP268227
- DOI -
- Views 107
- Downloads 0
Structure of the chorioretinal complex in the rabbit eye after vitrectomy. Report 2. Vitreous cavity irrigation with different temperature solutions for 60 minutes
Background: It remains poorly understood what should be the temperature of the irrigation solution for intraocular surgery and how long it is reasonable to use irrigation solutions during vitrectomy. Purpose: To investi...
Prevalence of and risk factors for diabetic retinopathy in areas differing in local access to endocrinologic care
Purpose: To investigate the prevalence of and risk factors for diabetic retinopathy in areas differing in access to endocrinologic care. Materials and Methods: The study was conducted in the Ganja-Gazakh economic region...
New risk factors for post-surgical recurrent diabetic maculopathy in type 2 diabetes mellitus
Background: Some pathogenetic risk factors (platelet-derived growth factor (PDGF); tumor necrosis factor alpha (TNFα); and Endothelin-1 (ET1)) are involved in the development of diabetic maculopathy (DMP) in type 2 diabe...
Primary open-angle glaucoma progression depending on clinical indices at presentation
Background: Given the importance of developing simple and efficient methods for the diagnosis and prognosis of primary open-angle glaucoma (POAG), we have previously proposed an index of progression of glaucoma stage (IP...
Choroidal thickness in patients with progressive and stabilized POAG
Purpose: To investigate choroidal thickness in patients with progressive and stabilized primary open-angle glaucoma (POAG). Materials and Methods: Forty-nine patients (87 eyes; age, 52 to 77 years) with stage 1, 2 or 3...